Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

New research entertains the theory of antidepressant efficacy as early-COVID-19 treatment

Staff Writer
Staff Writer 2 years ago
Updated 2021/10/29 at 1:45 AM
Share
SHARE

A group of researchers has entertained the theory of antidepressant use for early treatment of COVID-19, with potential efficacious outcomes.

In a study published by the Lancet, researchers suggested that the antidepressant drug fluvoxamine may provide some extent of efficacy for the early treatment of COVID-19 among acutely symptomatic patients.

For the study, nearly 10,000 people were screened, as part of a clinical trial that began on June 2nd, 2020. As many as 741 participants were administered fluvoxamine, while the other 756 a placebo.

According to the Lancet study: “This is, to the best of our knowledge, the first large, randomised controlled trial to test the efficacy of fluvoxamine for acute treatment of COVID-19. We found a clinically important absolute risk reduction of 5·0%, and 32% RR reduction, on the primary outcome of hospitalization.”

Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation.”

Photo: Getty Images

You Might Also Like

Study boasts MDMA-assisted therapy for PTSD patients

How the brain is organized is revealed by the largest genetic study of brain structure to date

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

New study reveals positive results from postpartum depression treatment Zuranolone

New study explores magic mushrooms for anorexia nervosa psychopathology

TAGGED: COVID-19, mental health, antidepressants
Staff Writer October 28, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Brisk walking may reduce the severity of symptoms associated with postpartum depression
Next Article Widespread availability of fast food joints may explain the high incidences of type 2 diabetes

Recommended

Clinical

Study boasts MDMA-assisted therapy for PTSD patients

1 Min Read
Clinical

How the brain is organized is revealed by the largest genetic study of brain structure to date

2 Min Read
Clinical

Study investigates the ethical implications of combining the analysis of ancient DNA and data from private genetic databases

3 Min Read
Clinical

New study reveals positive results from postpartum depression treatment Zuranolone

2 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?